Cargando…

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 blockade therapy has been trialed in a broad range of malignancies and achieved clinical success. Despite the potentially cure-like...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jin-Yu, Zhang, Dengke, Wu, Songquan, Xu, Min, Zhou, Xiao, Lu, Xiao-Jie, Ji, Jiansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450549/
https://www.ncbi.nlm.nih.gov/pubmed/32864132
http://dx.doi.org/10.1186/s40364-020-00212-5
_version_ 1783574825337356288
author Sun, Jin-Yu
Zhang, Dengke
Wu, Songquan
Xu, Min
Zhou, Xiao
Lu, Xiao-Jie
Ji, Jiansong
author_facet Sun, Jin-Yu
Zhang, Dengke
Wu, Songquan
Xu, Min
Zhou, Xiao
Lu, Xiao-Jie
Ji, Jiansong
author_sort Sun, Jin-Yu
collection PubMed
description PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 blockade therapy has been trialed in a broad range of malignancies and achieved clinical success. Despite the potentially cure-like survival benefit, only a minority of patients are estimated to experience a positive response to PD-1/PD-L1 blockade therapy, and the primary or acquired resistance might eventually lead to cancer progression in patients with clinical responses. Accordingly, the resistance to PD-1/PD-L1 blockade remains a significant challenge hindering its further application. To overcome the limitation in therapy resistance, substantial effort has been made to improve or develop novel anti-PD-1/PD-L1 based immunotherapy strategies with better clinical response and reduced immune-mediated toxicity. In this review, we provide an overview on the resistance to PD-1/PD-L1 blockade and briefly introduce the mechanisms underlying therapy resistance. Moreover, we summarize potential predictive factors for the resistance to PD-1/PD-L1 blockade. Furthermore, we give an insight into the possible solutions to improve efficacy and clinical response. In the following research, combined efforts of basic researchers and clinicians are required to address the limitation of therapy resistance.
format Online
Article
Text
id pubmed-7450549
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74505492020-08-28 Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives Sun, Jin-Yu Zhang, Dengke Wu, Songquan Xu, Min Zhou, Xiao Lu, Xiao-Jie Ji, Jiansong Biomark Res Review PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 blockade therapy has been trialed in a broad range of malignancies and achieved clinical success. Despite the potentially cure-like survival benefit, only a minority of patients are estimated to experience a positive response to PD-1/PD-L1 blockade therapy, and the primary or acquired resistance might eventually lead to cancer progression in patients with clinical responses. Accordingly, the resistance to PD-1/PD-L1 blockade remains a significant challenge hindering its further application. To overcome the limitation in therapy resistance, substantial effort has been made to improve or develop novel anti-PD-1/PD-L1 based immunotherapy strategies with better clinical response and reduced immune-mediated toxicity. In this review, we provide an overview on the resistance to PD-1/PD-L1 blockade and briefly introduce the mechanisms underlying therapy resistance. Moreover, we summarize potential predictive factors for the resistance to PD-1/PD-L1 blockade. Furthermore, we give an insight into the possible solutions to improve efficacy and clinical response. In the following research, combined efforts of basic researchers and clinicians are required to address the limitation of therapy resistance. BioMed Central 2020-08-26 /pmc/articles/PMC7450549/ /pubmed/32864132 http://dx.doi.org/10.1186/s40364-020-00212-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Sun, Jin-Yu
Zhang, Dengke
Wu, Songquan
Xu, Min
Zhou, Xiao
Lu, Xiao-Jie
Ji, Jiansong
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
title Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
title_full Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
title_fullStr Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
title_full_unstemmed Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
title_short Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
title_sort resistance to pd-1/pd-l1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450549/
https://www.ncbi.nlm.nih.gov/pubmed/32864132
http://dx.doi.org/10.1186/s40364-020-00212-5
work_keys_str_mv AT sunjinyu resistancetopd1pdl1blockadecancerimmunotherapymechanismspredictivefactorsandfutureperspectives
AT zhangdengke resistancetopd1pdl1blockadecancerimmunotherapymechanismspredictivefactorsandfutureperspectives
AT wusongquan resistancetopd1pdl1blockadecancerimmunotherapymechanismspredictivefactorsandfutureperspectives
AT xumin resistancetopd1pdl1blockadecancerimmunotherapymechanismspredictivefactorsandfutureperspectives
AT zhouxiao resistancetopd1pdl1blockadecancerimmunotherapymechanismspredictivefactorsandfutureperspectives
AT luxiaojie resistancetopd1pdl1blockadecancerimmunotherapymechanismspredictivefactorsandfutureperspectives
AT jijiansong resistancetopd1pdl1blockadecancerimmunotherapymechanismspredictivefactorsandfutureperspectives